By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.




Founder: Edward Robinson Squibb

CEO: Giovanni Caforio, MD

CFO: Charles Bancroft


Please click here for clinical trial information.


Please click here for Bristol-Myers Squibb job opportunities.


Please click here to see all products.

For more information, visit and follow us on


Key Statistics

Ownership: Public

Web Site: Bristol-Myers Squibb
Symbol: BMY



PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech  - Cancer

Gilead (Seattle, WA) 

Company News
Bristol-Myers Squibb (BMY) to Revamp R&D and Streamline Operations After Opdivo Failure 10/27/2016 6:04:33 AM
Bristol-Myers Squibb (BMY) Release: New Results Presented For Opdivo (Nivolumab) Demonstrate Encouraging Response Rate In An Expanded Population Of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients 10/25/2016 11:18:21 AM
Bristol-Myers Squibb (BMY)'s Coast 2 Coast 4 Cancer Ride Raises Over $1 Million For Cancer Research 10/24/2016 12:09:01 PM
Bristol-Myers Squibb (BMY) Release: FDA Accepts For Priority Review The Supplemental Biologics License Application For Opdivo (Nivolumab) In Previously Treated Patients With Advanced Form Of Bladder Cancer 10/24/2016 12:01:12 PM
Bristol-Myers Squibb Foundation Joins White House Cancer Moonshot 10/17/2016 10:53:24 AM
Comeback Kid Exelixis (EXEL) Could Pose a Huge Threat to Biotech Giants Bristol-Myers Squibb (BMY) and Pfizer (PFE) 10/17/2016 7:00:07 AM
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion For Opdivo(Nivolumab) For The Treatment Of Adult Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant And Treatment With Brentuximab Vedotin 10/14/2016 11:48:08 AM
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin 10/14/2016 6:56:22 AM
Bristol-Myers Squibb (BMY) Release: Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer 10/10/2016 6:23:01 AM
Bristol-Myers Squibb (BMY) Looks Over Its Shoulder as Opdivo Disappoints While Merck & Co. (MRK)'s Keytruda Shines in Lung Cancer Study 10/10/2016 6:00:35 AM